Distribution of IL-5 Receptor-positive B Cells. Expression of IL-5 Receptor on Ly-1(CD5)+ B Cells
Overview
Affiliations
mAb to murine IL-5R were prepared by means of fusion between mouse myeloma cells and spleen cells from a rat immunized with membrane-enriched fractions of IL-5-dependent early B cell line (T88-M). Two mAb (H7 and T21) were selected for their competitive inhibition of receptor binding by 35S-labeled IL-5 and of IL-5 biologic activities. The number of binding sites recognized by the mAb on different cell lines correlated with IL-5 responsiveness. Most surface IgM+ peritoneal B cells were H7+ and more than 70% were also Ly-1(CD5)dull+, and responded to IL-5 for polyclonal IgM production in a high frequency. A significant proportion of splenic B cells reacted with these mAb, although lower number (one-log less) than peritoneal B cells and a small proportion of H7dull+ splenic B cells seems to be Ly-1(CD5)dull+, 1 of 200 splenic B cells responded to IL-5 for IgM production. These results suggest that IL-5R+ B cells may consist of a subpopulation of B cells. Intriguingly, lymphoid populations of bone marrow cells were stained with H7 and T21, whereas myeloid populations were brightly stained with only T21. Finally, both H7 and T21 mAb specifically precipitated a protein of a Mr 60,000 from 125I-labeled cell lysates of IL-5R+ T88-M cells. The IL-5R with similar size (Mr 55,000 to 60,000) was precipitated from the cell lysates of peritoneal B cells. T21 mAb but not H7 mAb precipitated a protein of a Mr 110,000 from the cell lysates of bone marrow cells.
B-cell and plasma cell activation in a mouse model of chronic muscle pain.
Lenert M, Green A, Merriwether E, Burton M Neurobiol Pain. 2024; 16:100169.
PMID: 39507010 PMC: 11539501. DOI: 10.1016/j.ynpai.2024.100169.
Hayakawa K, Zhou Y, Shinton S Immun Ageing. 2024; 21(1):22.
PMID: 38570827 PMC: 10988983. DOI: 10.1186/s12979-024-00415-6.
Ying Z, Hardikar S, Plummer J, Hamidi T, Liu B, Chen Y Cell Mol Immunol. 2023; 20(12):1487-1498.
PMID: 37990035 PMC: 10687020. DOI: 10.1038/s41423-023-01106-w.
Jaufmann J, Carevic M, Tumen L, Eliacik D, Schmitt F, Hartl D Immun Inflamm Dis. 2020; 9(1):210-222.
PMID: 33226189 PMC: 7860589. DOI: 10.1002/iid3.380.
A new dawn for eosinophils in the tumour microenvironment.
Grisaru-Tal S, Itan M, Klion A, Munitz A Nat Rev Cancer. 2020; 20(10):594-607.
PMID: 32678342 DOI: 10.1038/s41568-020-0283-9.